The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia

Author： Nakou ES   Filippatos TD   Kiortsis DN   Derdemezis CS   Tselepis AD   Mikhailidis DP   Elisaf MS  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.9, Iss.18, 2008-12, pp. : 3151-3158

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effect of Gemfibrozil on HDL-Associated Serum Paraoxonase Activity and Lipoprotein Profile in Patients with Hyperlipidaemia

By Paragh G.   Balogh Z.   Seres I.   Harangi M.   Boda J.   Kovacs P.  

Clinical Drug Investigation, Vol. 19, Iss. 4, 2000-04 ,pp. : 277-282

Adis International

Access to resources Recommend Favorite

Validation of the reconstituted high-density lipoprotein (rHDL) drug delivery platform using dilauryl fluorescein (DLF)

By McConathy Walter  

Drug Delivery and Translational Research, Vol. 1, Iss. 2, 2011-04 ,pp. : 113-120

Springer Publishing Company

Access to resources Recommend Favorite

Micronized Fenofibrate in Dyslipidemia: A Focus on Plasma High-Density Lipoprotein Cholesterol (HDL-C) Levels

By Sharpe M.   Ormrod D.   Jarvis B.  

American Journal of Cardiovascular Drugs, Vol. 2, Iss. 2, 2002-02 ,pp. : 125-132

Adis International

Access to resources Recommend Favorite

Treating High Density Lipoprotein Cholesterol (HDL-C): Quantity Versus Quality

By  

Current Pharmaceutical Design, Vol. 19, Iss. 21, 2013-06 ,pp. : 3841-3857

Bentham Science Publishers

Access to resources Recommend Favorite

Significance of High Density Lipoprotein-Cholesterol in Cardiovascular Risk Prevention: Recommendations of the HDL Forum1 1 Affiliation details for individual members of the HDL Forum are available in the Acknowledgments section.

By Juan F. Ascaso  

American Journal of Cardiovascular Drugs, Vol. 4, Iss. 5, 2004-01 ,pp. : 299-314

Adis International

Access to resources Recommend Favorite